´"Kit COVID-19"
Goiás (Estado). Secretaria de Estado da Saúde; Subsecretaria de Saúde; Núcleo de Evidências.
Goiânia; SES-GO; 10 jul. 2020. 1-7 p.
Não convencional em Português | SES-GO, Coleciona SUS (Brasil), CONASS, LILACS | ID: biblio-1116448
Documentos relacionados
The critical pharmaceutical situation in Sudan 2023: A humanitarian catastrophe of civil war.
Pharmaceutical industry relationships with oncologists in sub-Saharan Africa.
Sales of "COVID kit" drugs and adverse drug reactions reported by the Brazilian Health Regulatory Agency.
Gender bias in antidepressant direct-to-consumer pharmaceutical advertising.
Alcohol and other drugs in suicide in Canada: opportunities to support prevention through enhanced monitoring.
Encodat 2016: Violencia de pareja y uso de tabaco, alcohol y drogas. Nuevos retos para la salud mental.
Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.
Examining Factors Associated with Non-Fatal Overdose among People Who Inject Drugs in Rural Appalachia.
Effects of home drug delivery on drug-related problems: preliminary evidence for improved patient outcomes during the COVID-19 pandemic in Thailand.
Prevalence and correlates of non-fatal overdose among people who use drugs: findings from rapid assessments in Massachusetts, 2017-2019.